XML 64 R49.htm IDEA: XBRL DOCUMENT v3.25.1
ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details)
€ in Millions, shares in Millions, $ in Millions
1 Months Ended 3 Months Ended
Jan. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Jan. 31, 2024
USD ($)
shares
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Jan. 31, 2025
EUR (€)
Dec. 31, 2024
designee
Business Combination, Separately Recognized Transactions [Line Items]              
Acquired in-process research and development expenses       $ 253 $ 4,131    
Arcus              
Business Combination, Separately Recognized Transactions [Line Items]              
Additional interest acquired, shares (in shares) | shares     15.2        
Additional equity investment     $ 320        
Option fee     100        
Number of designees | designee             3
Arcus | Prepaid and other current assets              
Business Combination, Separately Recognized Transactions [Line Items]              
Additional equity investment     $ 233        
LEO Pharma A/S Agreement | LEO Pharma A/S              
Business Combination, Separately Recognized Transactions [Line Items]              
Payments to acquire in process research and development $ 250            
Additional payments (up to) 1,500            
SpinCo | Galapagos Subscription Agreement              
Business Combination, Separately Recognized Transactions [Line Items]              
Initial capital allocation (up to) $ 2,540         € 2,450  
Ownership (as a percent) 25.00%         25.00%  
Galapagos | Galapagos Subscription Agreement              
Business Combination, Separately Recognized Transactions [Line Items]              
Ownership (as a percent) 25.00%         25.00%  
Arcus              
Business Combination, Separately Recognized Transactions [Line Items]              
Ownership (as a percent)     30.00%        
Ownership interest, shares (in shares) | shares     31.4        
Other (Income) Expense | Arcus              
Business Combination, Separately Recognized Transactions [Line Items]              
Additional equity investment, premium     $ 87        
CymaBay              
Business Combination, Separately Recognized Transactions [Line Items]              
Total consideration transferred   $ 3,900          
Acquired in-process research and development expenses         3,900    
Share-based compensation expense         133    
CymaBay | Research and Development Expense              
Business Combination, Separately Recognized Transactions [Line Items]              
Share-based compensation expense         67    
CymaBay | Selling, General and Administrative Expenses              
Business Combination, Separately Recognized Transactions [Line Items]              
Share-based compensation expense         $ 67